Skip to main content

Table 1 Schedule of patient assessments

From: Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol

 

Baseline

Day 1

3 months (± 14 days)

6 months (± 14 days)

9 months (± 14 days)

12 months (± 14 days)

18 months (± 14 days)

24 months (± 14 days)

Assessment

 Informed consent

√

       

 CT of pelvis/abdomena

√

  

√

 

√

√

√

 CT chest (or chest X-ray)

√

  

√

 

√

√

√

 MRI of pelvis

√

  

√

 

√

√

√

 Pelvic ultrasonographyb

√

 

√

√

√

√

√

√

 CA125

√

 

√

√

√

√

√

√

 FBG (fasting blood-glucose)

√

 

√

√

√

√

√

√

 Serum or urine pregnancy test

√

√(urine)

      

 Fasting blood sugar

√

 

√

√

√

√

√

√

 HbA1c

√

 

√

√

√

√

√

√

 HE4 (human epididymal protein4)

√

 

√

√

√

√

√

√

 Blood collection for biomarkers and genetic testing

√

       

 ERα, PRα and PRβ (estrogen receptor, progesterone receptor)

 Medical history

√

       

 Concomitant medications

√

 

√

√

√

√

√

√

 ECOG

√

 

√

√

√

√

√

√

 Height

√

       

 Weight

√

 

√

√

√

√

√

√

 BMI

√

 

√

√

√

√

√

√

 Surgical, medical, gynecologic, and family history

√

       

 Self-efficacy and social support questionnaire

√

 

√

√

√

√

√

√

 Adverse events

  

√

√

√

√

√

√

 Hysteroscopy, D&C

  

√

√

√

√

√

√

 Intervention adherence

  

√

√

√

√

√

√

  1. BMI body mass index, CA125 cancer antigen 125, CT computed tomography, D&C dilation and curettage, ECOG Eastern Cooperative Oncology Group, HbA1c glycosylated hemoglobin, MRI magnetic resonance imaging
  2. aCT scans will be performed every 6 months. However, if the ultrasound shows obvious lesions in the uterine cavity and tissue pathological examination indicates no remission or the disease has progressed, additional CT examination will be performed
  3. bPatients will receive pelvic ultrasonography and hysteroscopic and curettage every 3 months for endometrial pathological examination. If the ultrasound shows obvious lesions in the uterine cavity and tissue pathological examination indicates no remission or the disease has progressed, additional CT/MRI examination will be performed